Literature DB >> 17038473

Natalizumab and progressive multifocal leucoencephalopathy.

J R Berger1.   

Abstract

Current data suggest that as many as 1 in 1000 treated individuals may develop progressive multifocal leucoencephalopathy (PML) in concert with the use of natalizumab. Natalizumab was withdrawn in early 2005. The present paper provides a comprehensive description of PML and reviews the role of natalizumab in the pathogenesis of PML. It is likely that use of drugs which cause specific perturbations of the immune system will be accompanied by similar rare infections. Thus researchers should be on the alert when using such agents in clinical trials.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17038473      PMCID： PMC1798374          DOI： 10.1136/ard.2006.058404

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


  90 in total

1.  Progressive multifocal leukoencephalopathy: failure of response to transfer factor and cytarabine.

Authors:  G V Horn; F O Bastian; J L Moake
Journal:  Neurology       Date:  1978-08       Impact factor: 9.910

2.  Progressive multifocal leucoencephalopathy with magnetic resonance imaging verification and therapeutic trials with interferon.

Authors:  K Tashiro; S Doi; F Moriwaka; Y Maruo; M Nomura
Journal:  J Neurol       Date:  1987-08       Impact factor: 4.849

3.  Progressive multifocal leukoencephalopathy in a male homosexual with T-cell immune deficiency.

Authors:  J R Miller; R E Barrett; C B Britton; M L Tapper; G S Bahr; P J Bruno; M D Marquardt; A P Hays; J G McMurtry; J B Weissman; M S Bruno
Journal:  N Engl J Med       Date:  1982-12-02       Impact factor: 91.245

4.  Progressive multifocal leukoencephalopathy.

Authors:  B R Brooks; D L Walker
Journal:  Neurol Clin       Date:  1984-05       Impact factor: 3.806

5.  Progressive multifocal leukoencephalopathy: a burnt-out case.

Authors:  R W Price; S Nielsen; B Horten; M Rubino; B Padgett; D Walker
Journal:  Ann Neurol       Date:  1983-05       Impact factor: 10.422

6.  Are astrocytes infected in progressive multifocal leukoencephalopathy (PML)?

Authors:  M Mázló; I Tariska
Journal:  Acta Neuropathol       Date:  1982       Impact factor: 17.088

7.  Progressive multifocal leukoencephalopathy in a patient with acquired immune deficiency syndrome.

Authors:  C Bernick; J B Gregorios
Journal:  Arch Neurol       Date:  1984-07

Review 8.  Progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. A review of the literature with a report of sixteen cases.

Authors:  J R Berger; B Kaszovitz; M J Post; G Dickinson
Journal:  Ann Intern Med       Date:  1987-07       Impact factor: 25.391

9.  Neurological complications of acquired immune deficiency syndrome: analysis of 50 patients.

Authors:  W D Snider; D M Simpson; S Nielsen; J W Gold; C E Metroka; J B Posner
Journal:  Ann Neurol       Date:  1983-10       Impact factor: 10.422

10.  Prolonged survival and partial recovery in AIDS-associated progressive multifocal leukoencephalopathy.

Authors:  J R Berger; L Mucke
Journal:  Neurology       Date:  1988-07       Impact factor: 9.910
View more
  16 in total

Review 1.  Practical considerations for nonclinical safety evaluation of therapeutic monoclonal antibodies.

Authors:  Carmel M Lynch; Bruce W Hart; Iqbal S Grewal
Journal:  MAbs       Date:  2009 Jan-Feb       Impact factor: 5.857

Review 2.  Immunotoxicity of monoclonal antibodies.

Authors:  Jacques Descotes
Journal:  MAbs       Date:  2009-03-19       Impact factor: 5.857

Review 3.  Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease.

Authors:  Luc J J Derijks; Dennis R Wong; Daniel W Hommes; Adriaan A van Bodegraven
Journal:  Clin Pharmacokinet       Date:  2018-09       Impact factor: 6.447

Review 4.  Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies.

Authors:  Frank R Brennan; Laura Dill Morton; Sebastian Spindeldreher; Andrea Kiessling; Roy Allenspach; Adam Hey; Patrick Y Muller; Werner Frings; Jennifer Sims
Journal:  MAbs       Date:  2010-05-23       Impact factor: 5.857

5.  Natalizumab therapy is associated with changes in serum JC virus antibody indices over time.

Authors:  John Peters; Eric Williamson
Journal:  J Neurol       Date:  2017-10-16       Impact factor: 4.849

Review 6.  [Progressive multifocal leukoencephalopathy. Undesirable side effect of immunotherapy].

Authors:  H-P Hartung; C Warnke; R Hohlfeld; B C Kieseier
Journal:  Nervenarzt       Date:  2009-10       Impact factor: 1.214

7.  Rapidly progressive cerebellar ataxia in West Wales.

Authors:  Khalid Ali; Reem Amin; Kathir G Yoganathan; Rob Powell
Journal:  BMJ Case Rep       Date:  2013-11-21

8.  Functional energetics of CD4+-cellular immunity in monoclonal antibody-associated progressive multifocal leukoencephalopathy in autoimmune disorders.

Authors:  Aiden Haghikia; Moritz Perrech; Bartosz Pula; Sabrina Ruhrmann; Anja Potthoff; Norbert H Brockmeyer; Susan Goelz; Heinz Wiendl; Hans Lindå; Tjalf Ziemssen; Sergio E Baranzini; Tor-Björn Käll; Dietmar Bengel; Tomas Olsson; Ralf Gold; Andrew Chan
Journal:  PLoS One       Date:  2011-04-20       Impact factor: 3.240

9.  Analysis of behavior and trafficking of dendritic cells within the brain during toxoplasmic encephalitis.

Authors:  Beena John; Brendon Ricart; Elia D Tait Wojno; Tajie H Harris; Louise M Randall; David A Christian; Beth Gregg; Daniel Manzoni De Almeida; Wolfgang Weninger; Daniel A Hammer; Christopher A Hunter
Journal:  PLoS Pathog       Date:  2011-09-15       Impact factor: 6.823

10.  Pre-existing T- and B-cell defects in one progressive multifocal leukoencephalopathy patient.

Authors:  Alessandra Sottini; Ruggero Capra; Cinzia Zanotti; Marco Chiarini; Federico Serana; Doris Ricotta; Luigi Caimi; Luisa Imberti
Journal:  PLoS One       Date:  2012-04-04       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.